From targeted therapies to managing side effects, this year’s American Society of Clinical Oncology (ASCO) Annual Meeting unveiled exciting research in breast cancer care. In part two of our ASCO 2025 recap, we’ve compiled more breast cancer data coming out of this global event that could influence your treatment plan, depending upon your specific diagnosis.
Read part one of our ASCO recap here.
The phase III VERITAC-2 trial revealed vepdegestrant improved progression-free survival (PFS) in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer compared to the current treatment, fulvestrant. Based on these results, the U.S. Food and Drug Administration has given vepdegestrant fast-track designation. This data is significant because vepdegestrant is the first PROTAC drug tested in a phase III trial and shows promise as a new treatment option for this subgroup.
According to the phase III OASIS-4 trial, elinzanetant helped reduce hot flashes in women taking hormone therapy for HR-positive breast cancer or prevention. At the end of 12 weeks, 73% of participants taking elinzanetant reported their hot flashes had reduced by half. This offers a non-hormonal option for patients to manage hot flashes from breast cancer treatment and enhance quality of life.
Data from the international trial, INAVO120, revealed that a combination treatment of two targeted drugs (inavolisib and palbociclib) plus a hormone therapy (fulvestrant) significantly improved survival and delayed progression of disease for patients with PIK3CA-mutated HR+, HER2- breast cancer. This is significant because PIK3CA mutations are found in up to 40% of HR+, HER2- breast cancers and this triple therapy could become the new standard treatment for patients.
Explore additional research takeaways from ASCO 2025 here. Stay informed on the latest news in breast cancer research and download the Outcomes4Me app. Enable notifications so we can send you important updates.
